% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Long:305455,
      author       = {G. V. Long and C. Garnett-Benson and S. Dolfi and P. A.
                      Ascierto and J. Guo and A. A. Tarhini and S. Chandra and E.
                      Muñoz-Couselo and M. Del Vecchio and A. C. de Melo and M.
                      Callahan and H. Gogas and R. Dummer and D. Schadendorf$^*$
                      and P. Koelblinger and G. Quereux and I. Thomas and J. X. Yu
                      and A. Fisher and B. Wang and P. Djidel and A. Chouzy and M.
                      Semaan and B. Chen and A. M. Y. Cheong and H. A. Tawbi},
      title        = {{A}djuvant nivolumab and relatlimab in stage {III}/{IV}
                      melanoma: the randomized phase 3 {RELATIVITY}-098 trial.},
      journal      = {Nature medicine},
      volume       = {nn},
      issn         = {1078-8956},
      address      = {[New York, NY]},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2025-02173},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Based on RELATIVITY-047, nivolumab plus relatlimab is
                      approved for advanced melanoma. Here, to address a current
                      unmet need for more efficacious adjuvant regimens for
                      completely resected melanoma, the phase 3, double-blind
                      RELATIVITY-098 trial compared adjuvant nivolumab plus
                      relatlimab to nivolumab after complete resection of stage
                      III/IV melanoma. Patients were randomized 1:1 to receive
                      nivolumab 480 mg plus relatlimab 160 mg (n = 547) or
                      nivolumab 480 mg (n = 546) intravenously every 4 weeks for
                      ≤1 year; safety populations totaled 543 and 545 patients,
                      respectively. The primary endpoint was recurrence-free
                      survival (RFS), and the key secondary was overall survival;
                      translational endpoints were exploratory. There was no
                      difference in RFS for nivolumab plus relatlimab versus
                      nivolumab (hazard ratio = 1.01; $95\%$ confidence interval:
                      0.83-1.22; P = 0.928); therefore, overall survival was not
                      tested. Translational data across trials showed lower
                      circulating LAG-3+ T cells in the adjuvant setting
                      (RELATIVITY-098) versus advanced melanoma (RELATIVITY-047),
                      where LAG-3+ T cells were enriched in tumor versus blood.
                      The absence of macroscopic tumor and reduced peripheral
                      LAG-3+ T cells may explain the lack of added benefit of
                      nivolumab plus relatlimab over nivolumab in resected versus
                      metastatic melanoma. ClinicalTrials.gov identifier:
                      NCT05002569 .},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41109920},
      doi          = {10.1038/s41591-025-04032-8},
      url          = {https://inrepo02.dkfz.de/record/305455},
}